Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared an article by Aurelien Marabelle, et al. on X:
“PEM in MSI and dMMR advanced solid tumors: updated results KN-158 trial.
Phase II KN-158. N=373:
- ORR 33.8%.
- DoR 63.2 mo, OS 19.8 mo, PFS 4 mo.
- Grade ≥3 TRAEs: 13%.
Supports pembrolizumab use in MSI-H/dMMR solid tumors.”
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Authors: Aurelien Marabelle, et al.
